A Critical Month for BioNTech: Financials, Legal Battles, and the Oncology Pipeline

BioNTech faces a pivotal March with 2025 results and a high-stakes mRNA patent lawsuit against Moderna, as its cash-rich future hinges on oncology trials.

March represents a pivotal period for BioNTech, with significant financial and legal developments converging. The company is scheduled to release its full-year 2025 results on March 10th. Concurrently, a high-stakes patent lawsuit it has filed against rival Moderna underscores the fierce competition over foundational mRNA technology, placing the firm's future business model under intense scrutiny.

Financial Fortitude and Legal Crossfire

The upcoming earnings report arrives at a delicate juncture. BioNTech previously raised its 2025 revenue guidance to a range of €2.6 to €2.8 billion. This upward revision was partly driven by a $1.5 billion payment received through its collaboration with Bristol Myers Squibb. However, management has also communicated that no oncology product revenues are projected for 2026. While the company's cash reserves remain substantial at €17.2 billion, investors are keenly assessing how long this war chest must last in the absence of significant new sales.

Simultaneously, BioNTech has initiated legal proceedings against Moderna in a U.S. federal court. The complaint alleges that Moderna's COVID-19 vaccine, mNEXSPIKE, infringes upon BioNTech patents. The disputed technology focuses on specific regions of the spike protein rather than its entire structure—an approach BioNTech claims enables a potent immune response at lower doses and improves storage stability. Moderna reported vaccine sales of $1.17 billion through Q3 2025, with mNEXSPIKE forecasted to constitute approximately 55% of its COVID-19 vaccine sales for the 2025/26 season. BioNTech is seeking damages.

This dispute is not one-sided. Moderna had previously sued both BioNTech and Pfizer for patent infringement. In a separate but related development, Moderna reached a settlement in July 2026 with Genevant and Arbutus concerning lipid nanoparticle technology, involving a $950 million upfront payment and an additional $1.3 billion contingent on an appeal outcome. These figures highlight the enormous financial stakes involved in these intellectual property battles.

The Long-Term Bet on Cancer Therapeutics

Beyond the courtroom, the company's strategic focus is firmly on its oncology pipeline. BioNTech aims to have a total of 15 Phase III trials underway by the end of 2026. Currently, nine are active, with six more slated to commence this year. Seven late-stage data readouts are planned for 2026, with at least 17 anticipated by 2030 and beyond. The development portfolio targets lung, breast, gastrointestinal, urogenital, and gynecological cancers.

A key asset under watch is Pumitamig (BNT327/BMS986545), a candidate co-developed with Bristol Myers Squibb that has already generated Phase II data in triple-negative breast cancer. Over ten combination clinical studies are evaluating Pumitamig alongside other immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies.

To bolster its mRNA capabilities, BioNTech recently completed the acquisition of CureVac, aiming to enhance expertise in design, manufacturing, and formulation. Furthermore, the company appointed Kylie Jimenez as Chief People Officer in early March to lead the human resources strategy for its transformation into a multi-product oncology enterprise.

Balance Sheet Signals Strategic Patience

Key financial metrics depict an organization preparing for a potentially extended transition phase. The debt-to-equity ratio stands at a minimal 0.01, while short-term liquidity is exceptionally strong, evidenced by a current ratio of 7.12. For a clinical-stage biotech, this cushion is notable—and arguably necessary to bridge what may be several years without product-derived income.

The March 10th conference call, scheduled for 2:00 PM CET, will provide more than just figures. Management's commentary is expected to shed light on BioNTech's perspective regarding the Moderna litigation, the trajectory of vaccine revenue, and research priorities. The company has already revised its spending on research, administration, and investments downward, signaling a disciplined approach to cost management.

Trading in a volatile environment, BioNTech shares reflect a market valuation of approximately $24.8 billion. The central question for investors is no longer whether the company possesses the financial endurance to survive—it clearly does. The critical uncertainty is whether its oncology pipeline will deliver clinical and commercial success before investor patience wears thin.